Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388850 | 0.88 | MAP2K1 (0.51) | MAP2K1MAP2K2L3MBTL1 | |
| SCHEMBL27679386 | 0.88 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL3456426 | 0.86 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL3456059 | 0.85 | MAP2K1 (0.61) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL486563 | 0.85 | MAP2K1 (0.69) | MAP2K1MAP2K2 | |
| SCHEMBL29425363 | 0.85 | MAP2K1 (0.69) | MAP2K1MAP2K2 | |
| SCHEMBL13070282 | 0.85 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL3455931 | 0.84 | MAP2K1 (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL393267 | 0.84 | MAP2K1 (0.60) | MAP2K1MAP2K2ALOX15TSHR | |
| SCHEMBL2361868 | 0.83 | MAP2K1 (0.52) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | claimed |
| EP-1682138-B3 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2013-01-09 | — | — | EP | claimed |
| CN-102633716-A | Bicyclic inhibitors of mek and methods of use thereof | ARRAY BIOPHARMA INC | 2012-08-15 | — | — | CN | claimed |
| US-8211921-B2 | Heterocyclic inhibitors of MEK and methods of use | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | claimed |
| EP-2251327-A2 | Heterocyclic inhibitors of MEK and methods of use thereof | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | claimed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | claimed |
| JP-2007511614-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1905873-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2007-01-31 | — | — | CN | claimed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | claimed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | claimed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | MAP2K1 88/4885MAP2K2 71/4885NPC1 3788/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 87/4885MAP2K2 73/4885NPC1 3766/4885 |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 100/4885MAP2K2 78/4885NPC1 3910/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 82/4885MAP2K2 69/4885NPC1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.